Table 2 Bayesian analysis of E1690 using E1684 as historical data
From: Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690
Endpoint | Weight (a 0) | Posterior hazard ratio | 95% HPD Interval | % Reduction | Posterior cure rate estimate (95% HPD Interval) | |
|---|---|---|---|---|---|---|
OBS | IFN | |||||
RFS | 0 | 1.29 | (0.98, 1.63) | 29 | 0.32 | 0.41 |
(0.24, 0.39) | (0.32, 0.49) | |||||
0.4 | 1.32 | (1.04, 1.62) | 32 | 0.30 | 0.40 | |
(0.23, 0.36) | (0.33, 0.46) | |||||
1 | 1.34 | (1.10, 1.60) | 34 | 0.28 | 0.39 | |
(0.23, 0.33) | (0.33, 0.44) | |||||
OS | 0 | 1.01 | (0.74, 1.30) | 1 | 0.50 | 0.50 |
(0.42, 0.58) | (0.42, 0.58) | |||||
0.4 | 1.08 | (0.82, 1.34) | 8 | 0.44 | 0.46 | |
(0.36, 0.51) | (0.38, 0.54) | |||||
1 | 1.14 | (0.91, 1.38) | 14 | 0.39 | 0.43 | |
(0.32, 0.46) | (0.36, 0.50) | |||||